Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The company received gross proceeds of approximately US$1.7 million and net proceeds,
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Express Scripts to add Zepbound to National Preferred Formulary
Subscribe To Our Newsletter & Stay Updated
